First-Line Therapy for Chronic GvHD

Opinion
Video

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Related Videos
Video 5 - "Efficacy and Safety of Tumor Agnostic Therapies"
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Annie Im, MD, FASCO
Elias Jabbour, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Marc J. Braunstein, MD, PhD
Related Content
Chao Cao, PhD, MPH

More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study

April 25th 2024
Article
Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

March 28th 2024
Podcast
He Huang, MD, PhD, of First Affiliated Hospital, Zhejiang University School of Medicine

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
US FDA

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

April 22nd 2024
Article
Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists & Research Institute

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024
Article